Search results
Relay Therapeutics, Inc. (RLAY) Reports Q3 Loss, Lags Revenue Estimates
Zacks via Yahoo Finance· 2 years agoRelay Therapeutics, Inc. (RLAY) delivered earnings and revenue surprises of -7.04% and 31.20%,...
Earnings Preview: Relay Therapeutics, Inc. (RLAY) Q4 Earnings Expected to Decline
Zacks via Yahoo Finance· 1 year agoRelay Therapeutics, Inc. (RLAY) doesn't possess the right combination of the two key ingredients for...
Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?
Zacks via Yahoo Finance· 4 months agoRelay Therapeutics, Inc. (RLAY) was a big mover last session on higher-than-average trading volume....
Relay Therapeutics Inc (RLAY) Reports Q3 2023 Financial Results: Revenue Surges to $25.2 Million
GuruFocus.com via Yahoo Finance· 7 months agoRelay Therapeutics Inc (NASDAQ:RLAY) reports Q3 2023 revenue of $25.2 million, a significant...
Relay Therapeutics, Inc.'s (NASDAQ:RLAY) Intrinsic Value Is Potentially 23% Below Its Share Price
Simply Wall St. via Yahoo Finance· 1 year agoToday we'll do a simple run through of a valuation method used to estimate the attractiveness of...
Wall Street Analysts Think Relay Therapeutics, Inc. (RLAY) Could Surge 94.78%: Read This Before...
Zacks via Yahoo Finance· 1 year agoThe average of price targets set by Wall Street analysts indicates a potential upside of 94.8% in...
Relay Therapeutics Inc (RLAY) Reports Full Year 2023 Financial Results and Corporate Highlights
GuruFocus.com via Yahoo Finance· 4 months agoCash Position: $750.1 million in cash, cash equivalents, and investments as of December 31, 2023. Revenue Growth: Full year 2023 revenue increased to $25.5 million, up from $1.4 million in 2022 ...
Relay Therapeutics Shares Jump After Interim Data From Bile Duct Cancer Drug Ahead Of ESMO...
Benzinga via Yahoo Finance· 2 years agoRelay Therapeutics Inc's (NASDAQ: RLAY) ReFocus trial for RLY-4008 was published on the European...